Advanced Science | Brain-Penetrant Nanobody Reveals GSK3β-Driven Proline-Directed Phosphorylation as a Master Regulator of Ischemic Neurodegeneration

This study provides a new strategy for the precision treatment of ischemic stroke, suggesting that interventions targeting specific active modules of GSK3β may be superior to traditional broad-spectrum inhibition, thereby pointing the way for the development of neuroprotective drugs.

 

Literature Overview

The article titled 'A Brain-Penetrant Nanobody Reveals GSK3β-Driven Proline-Directed Phosphorylation as a Master Regulator of Ischemic Neurodegeneration', published in Advanced Science, systematically explores the dual kinase activity mechanism of Glycogen Synthase Kinase 3β (GSK3β) in ischemic brain injury and develops a nanobody, Nb.29E9, capable of specifically targeting its proline-directed phosphorylation (S/T-P) domain.

Background Knowledge

Ischemic stroke is a leading cause of death and disability globally, with core pathological mechanisms involving complex cascades including excitotoxicity, oxidative stress, and neuroinflammation. GSK3β, a key kinase in neurons and glial cells, plays a central role in regulating neuronal survival and synaptic plasticity. However, a current bottleneck in research is that traditional small-molecule inhibitors cannot distinguish between the two distinct kinase activities of GSK3β: substrate-primed phosphorylation and proline-directed phosphorylation. While non-selective broad-spectrum inhibition can provide some neuroprotection, it interferes with physiological signaling, leading to off-target effects. Furthermore, blood-brain barrier (BBB) permeability remains a major obstacle limiting drug delivery to the central nervous system. This study leverages the unique structural advantages of nanobodies to precisely block the interaction interface between GSK3β and eIF4E2, thereby selectively inhibiting pathological S/T-P phosphorylation while preserving physiological signaling, combined with a ferritin nanoplatform to achieve brain-targeted delivery.

 

 

Research Methods and Experiments

The authors first constructed a fully synthetic yeast-displayed nanobody library and screened for high-affinity clones, specifically Nb.29E9, which binds to the surface loop of GSK3β (mediating eIF4E2 interaction) using flow cytometry (FACS). Binding specificity and function were verified using GST Pull-down, Co-IP, and Nb-PROTAC degradation assays. At the cellular level, an oxygen-glucose deprivation/reoxygenation (OGD/R) model was employed in HT22 neurons and BV2 microglia to evaluate the effects of Nb.29E9 on cell viability, apoptosis, oxidative stress, and inflammatory polarization. To overcome delivery barriers, the authors constructed MMP-9-responsive ferritin nanoparticles (TPNbT-CHFn). This system utilizes the TGN peptide to penetrate the BBB and carries neuron/glia-targeting peptides to achieve precise release within the ischemic microenvironment. At the animal level, a middle cerebral artery occlusion/reperfusion (MCAO/R) mouse model was established. Treatment efficacy was comprehensively assessed via TTC staining, behavioral tests, MRI imaging, and histopathological analysis. Additionally, phosphoproteomic analysis was conducted to systematically map the signal network reprogramming following intervention.

Key Conclusions and Perspectives

• The proline-directed kinase activity of GSK3β, rather than its substrate-primed activity, is the key pathological factor driving ischemic neurodegeneration. Data findings: Nb.29E9 significantly inhibits S/T-P phosphorylation of key substrates such as RBM38, HIF1α, and p53, thereby reducing cell apoptosis and oxidative stress. The guidance for subsequent signal pathway analysis is the necessity to distinguish between different kinase activity modes to develop more precise therapies.
• The nanobody Nb.29E9 reshapes the phosphorylation network, simultaneously regulating multiple key signaling pathways. Data findings: Phosphoproteomics revealed that Nb.29E9 specifically corrects pathological hyperphosphorylation of SMAD2/3 (TGF-β signaling), CAMKK2 (AMPK pathway), and AKT1S1 (mTORC1 regulation). The guidance for subsequent drug target validation is that these sites can serve as key biomarkers for evaluating the efficacy of neuroprotective drugs.
• The ferritin-based nanodelivery system achieves efficient brain targeting and cell-specific delivery of GSK3β inhibitors. Data findings: TPNbT-CHFn nanoparticles significantly reduced infarct volume, restored neurovascular integrity, and improved motor function in MCAO/R mice, showing consistent efficacy across both male and female mice. The guidance for subsequent drug delivery system development is that utilizing MMP-9 responsive release and cell-specific targeting peptides is an effective strategy to solve the challenges of CNS drug delivery.
• The intervention strategy effectively regulates neuroinflammatory responses. Data findings: Nb.29E9 treatment significantly reduced the expression of pro-inflammatory factors (IL-1β, IL-6, TNF-α) and promoted the polarization of microglia towards an anti-inflammatory phenotype (CD206+). The guidance for subsequent immunomodulatory therapy is that targeting kinase activity can serve as an upstream means to simultaneously regulate neuronal survival and glial inflammatory responses.

Research Significance and Prospects

This discovery has profound implications for drug development, demonstrating the feasibility of an 'activity-selective' regulation strategy targeting specific active modules of kinases (rather than the entire kinase) in neurodegenerative diseases, providing a new paradigm for developing highly selective, low-toxicity neuroprotective drugs. In terms of clinical monitoring, the identified S/T-P phosphorylation sites (e.g., RBM38-S195, p53-S315) are expected to become potential biomarkers for assessing the severity of ischemic injury and treatment response. Furthermore, the MMP-9 responsive nanodelivery platform established in this study provides a general technical reference for disease modeling and therapeutic applications of other protein-based drugs (such as antibodies and enzymes) that require BBB penetration, facilitating the leap from laboratory mechanistic discovery to clinical translation.

 

 

Conclusion

By developing an innovative brain-penetrant nanobody delivery system, this study for the first time clearly reveals the core pathogenic role of GSK3β-driven proline-directed phosphorylation in ischemic brain injury. This finding not only breaks the limitations of traditional broad-spectrum kinase inhibitors, providing new molecular targets and strategies for the precision treatment of ischemic stroke, but also demonstrates the immense potential of nanotechnology in overcoming the blood-brain barrier and achieving cell-specific drug administration. From laboratory mechanism elucidation to animal model validation, this study constructs a complete translational medicine pathway, emphasizing the importance of distinguishing between different kinase activity modes for understanding the pathological mechanisms of complex neurological diseases. In the future, drug development based on such activity-selective regulation strategies is expected to significantly improve the prognosis of patients with neurodegenerative diseases, laying a solid scientific and technological foundation for building a more comprehensive stroke care system.

 

Lan Li, Muyang Li, Lei Sun, Zhiqiang Dong, and Min Zhang. A Brain‐Penetrant Nanobody Reveals GSK3β‐Driven Proline‐Directed Phosphorylation as a Master Regulator of Ischemic Neurodegeneration. Advanced Science.